No. of patients evaluable/completing treatment |
74/76 |
Gender |
Male |
38 |
|
Female |
36 |
Age at treatment (years) |
Median |
61 (range 40-80) |
ECOG performance status |
Median |
0 (range 0-2) |
0 |
50 |
1 |
22 |
2 |
2 |
Status of extrahepatic disease |
|
NED (no evidence of disease) |
39 (53%) |
SD/PD (stable/progressive) |
35 (47%) |
Previous treatment per irradiated lesion |
|
No previous treatment |
23 (25.3%) |
Chemotherapy |
44 (48.4%) |
Endocrine therapy |
3 (3.3%) |
Local therapy (surgery, radiofrequency ablation) |
4 (4.4%) |
Combination of local and systemic treatment |
17 (18.6%) |
Follow up (months) |
Median |
15 (range 3-103) |
Primary tumor |
Colorectal |
37 |
|
Breast |
12 |
|
Esophageal |
5 |
|
Stomach/Pancreas/Bile duct |
7 |
|
Lung |
2 |
|
Other |
11 |
|
Lesions
|
Total No. of lesions evaluated/treated |
91/95 |
Lesions per patient |
Mean |
1.23 (range 1-4) |
Total PTV dose at 60-95% IDL |
Median |
35 (range 18-37.5) |
(Gy) |
|
Single PTV dose at 60-95% IDL |
Median |
7 (range 5-12.5) |
(Gy) |
|
Fractions |
Median |
5 (range 2-5) |
Minimum BED to GTV |
Median |
91.2 Gy (18.7-183.5Gy) |
Gross tumor volume GTV (cc) |
Median |
45 (range 1.3-699) |
<100 |
65 |
100-200 |
12 |
>200 |
12 |
Planning target volume PTV (cc) |
Median |
123 (range 10.6-1074) |